Meeting
2012 ASCO Annual Meeting
Serum hepatocyte growth factor and interleukin-6 as prognostic markers for stage III non-small cell lung cancer.
Authors
Hideki Ujiie
Department of Thoracic Surgery, Saitama Cancer Center, Saitama, Japan
Hideki Ujiie , Mikio Tomida , Hirohiko Akiyama , Daisuke Okada , Yuki Nakajima , Hiroshi Sakai , Yuichi Takiguchi , Hideki Tanzawa
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Genomic and Epigenomic Biomarkers
Citation
J Clin Oncol 30, 2012 (suppl; abstr 10542)
DOI
10.1200/jco.2012.30.15_suppl.10542
Abstract #
10542
Poster Bd #
42G
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206.
First Author: Harriet M. Kluger
Poster
2019 Gastrointestinal Cancers Symposium
Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.
First Author: Yingmiao Liu
Poster
2016 ASCO Annual Meeting
Prognostic and predictive blood-based biomarkers (BMs) in patients (pts) with advanced epithelial ovarian cancer (EOC) treated with carboplatin–paclitaxel (CP) ± bevacizumab (BEV): Results from GOG-0218.
First Author: Angeles Alvarez Secord
Poster
2016 Gastrointestinal Cancers Symposium
Possible role of the systemic inflammatory reaction in defining tumor responder vs. nonresponder in cancer macrobead therapy.
First Author: Barry H. Smith